The negative sentiment around his delay has been pretty short-sighted or potentially just a sorry attempt at creating doubt in the minds of holders.
This is a pharmaceutical company with a strong multi-indication candidate that has been repurposed with low safety risk and very competent people running the show. It has hit a typical delay from the FDA on some minor technical questions during an world-wide pandemic that has slowed the process. The feedback to date from all human trials and SAS has been outstanding.
I bought today and will buy again if it drops significantly again. This is one of those moments where a solid company with a good product is experiencing external issues that IMO are transient. Opportunity knocks.
GLTAH
Chart, page-2181
-
- There are more pages in this discussion • 2,179 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.81M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 29.0¢ | 25.5¢ | $430.3K | 1.585M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5500 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 36162 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |